Astrazeneca Plc · LSE:AZN
Astrazeneca — Shareholder Meeting (2007)
10 slides from Astrazeneca's shareholder meeting presentation, 2007
Slide 1: David R Brennan, Chief Executive Officer
David R Brennan Chief Executive Officer 1
Slide 2: Our purpose; Headline results 2006
Our purpose To make the most meaningful difference to patient health through great medicines Headline results 2006 2006 2005 Actual CER $m $m growth growth Sales 26,475 23,950 +11% +11% Operating profit 8,216 6,502 +26% +28% Operating margin 31.0% 27.2% +3.8 pts EPS $3.86 $2.91 +33% +34% Dividends $
Slide 3: Headline results 1Q 07
Headline results 1Q 07 2007 2006 Actual CER $m $m growth growth Sales 6,966 6,180 +13% +9% Operating profit 2,170 1,976 +10% +10% Reported EPS $1.02 $0.90 +13% +14% Restructuring $0.04 - Toprol-XL ($0.13) ($0.11) Adjusted EPS $0.93 $0.79 Key products @ Actual RoX 14,000 12,000 10,000 Sales $m 8,000
Slide 4: Sales by region 2006; A demanding and volatile environment
Sales by region 2006 Emerging Markets US Other Established CER 11% $m growth 6% Japan US 12,449 +16% 6% 47% ROW 14,026 +7% Established 11,162 +4% Markets 30% Emerging 2,864 +22% Western Markets Europe A demanding and volatile environment > Continuing unmet needs > Growing population > Ageing populat
Slide 5: Our purpose, principles and priorities
Our purpose, principles and priorities “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Our purpose, principles and priorities “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Valued medicines Strengthen the pipeline Products 5
Slide 6: Acquisitions and partnerships
Acquisitions and partnerships 2007 2005 > Saxagliptin > AGI-1067 (AtheroGenics) (Bristol-Myers Squibb) > Dapagliflozin > AZD3480 (Targacept) > Arrow Therapeutics > CytoFab™ (Protherics) > KuDOS 2006 > Cambridge Antibody Technology 3 acquisitions > Cubicin® (Cubist) 9 significant research > AZD3043 (
Slide 7: Pipeline 2004 - 2006
Pipeline 2004 - 2006 120 120 106 25 100 91 25 5 80 18 LCM 25 6 Phase III 13 60 5 23 Phase II 13 17 Phase I 40 17 Pre-clinical 45 49 20 31 0 FY 2004 FY 2005 FY 2006 Our purpose, principles and priorities “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Valued Customer
Slide 8: Our purpose, principles and priorities
Our purpose, principles and priorities “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Valued Customer-centric Lean and agile medicines mindset organisation Strengthen Grow the Reshape the pipeline business the business Products Patient Needs Performance Our purpose
Slide 9: Our purpose, principles and priorities
Our purpose, principles and priorities “MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH GREAT MEDICINES” Responsible Valued Customer-centric Lean and agile leaders who make medicines mindset organisation every interaction count Renew our Strengthen Grow the Reshape behaviour the pipe
Slide 10: David R Brennan, Chief Executive Officer
David R Brennan Chief Executive Officer 10